Compare VVX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | PHVS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2014 | 2021 |
| Metric | VVX | PHVS |
|---|---|---|
| Price | $65.72 | $25.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $62.60 | $39.44 |
| AVG Volume (30 Days) | ★ 397.9K | 254.3K |
| Earning Date | 02-23-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 791.53 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $4,419,142,000.00 | N/A |
| Revenue This Year | $4.53 | N/A |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $41.08 | $11.51 |
| 52 Week High | $65.50 | $29.80 |
| Indicator | VVX | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 50.74 |
| Support Level | $54.09 | $23.62 |
| Resistance Level | $56.38 | $27.11 |
| Average True Range (ATR) | 1.87 | 1.51 |
| MACD | 1.05 | -0.05 |
| Stochastic Oscillator | 91.12 | 40.33 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.